Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14926161 | 1.00 | ALDH1A1 (0.34) | ALDH1A1ADORA2AADORA2BADORA1CYP1A2 | |
| SCHEMBL18250759 | 0.84 | CYP1A2 (0.36) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL14857102 | 0.83 | KDM5A (0.32) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL14857100 | 0.83 | KDM5A (0.32) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL27831990 | 0.82 | ADORA2A (0.33) | ADORA2AADORA2BADORA1KDM5A | |
| SCHEMBL27867139 | 0.81 | CYP2C19 (0.41) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL8135609 | 0.81 | CYP1A2 (0.35) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL12812791 | 0.80 | CYP1A2 (0.33) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL27867156 | 0.80 | CYP2C19 (0.40) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL28807936 | 0.79 | KDM5A (0.32) | ADORA2AADORA2BADORA1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742168-B2 | Process for the production of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-06-03 | — | — | US | claimed |
| US-8637699-B2 | Process for the manufacture of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120310009-A1 | Process for the Production of Acetic Acid | LYONDELL CHEMICAL COMPANY (US) | 2012-12-06 | — | — | US | claimed |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | LYONDELLBASELL ACETYLS, LLC | 2012-10-18 | — | — | US | claimed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| WO-2021239643-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-12-02 | — | — | WO | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-9499529-B2 | Therapeutic uses of curcumin analogs for treatment of prostate cancer | CALIFORNIA STATE UNIVERSITY, FRESNO (US) | 2016-11-22 | — | — | US | disclosed |
| US-8742168-B2 | Process for the production of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8637699-B2 | Process for the manufacture of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| CN-101918368-B | Method for improving the hydrolysis stability of ionic liquids | BASF SE | 2013-04-24 | — | — | CN | disclosed |
| US-20120310009-A1 | Process for the Production of Acetic Acid | LYONDELL CHEMICAL COMPANY (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | LYONDELLBASELL ACETYLS, LLC | 2012-10-18 | — | — | US | disclosed |
| CN-102414241-A | Microencapsulated composition containing imidazole compound, curable composition using same, and masterbatch-type curing agent | ASAHI KASEI E MATERIALS CORP | 2012-04-11 | — | — | CN | disclosed |
| CN-101918368-A | Method for improving the hydrolysis stability of ionic liquids | BASF SE | 2010-12-15 | — | — | CN | disclosed |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASE SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2229365-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077452-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885ADORA2A 4351/4885ADORA2B 3375/4885 |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | DBI, IDH1, ACAD9 | ALDH1A1 69/4885ADORA2A 2605/4885ADORA2B 1670/4885 |
| US-20120310009-A1 | Process for the Production of Acetic Acid | DBI, FLI1, ACADM | ALDH1A1 52/4885ADORA2A 3389/4885ADORA2B 2830/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885ADORA2A 4351/4885ADORA2B 3375/4885 |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | LIPA, IDE, CEL | ALDH1A1 997/4885ADORA2A 3412/4885ADORA2B 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.